Amgen Inc. is a global biotechnology company dedicated to the discovery, development, manufacturing, and delivery of innovative human therapeutics across critical areas such as immunology, oncology, cardiovascular disease, bone health, and nephrology. Its business model centers on a diverse portfolio of medicines, including flagship products like Enbrel, Repatha, and Prolia, supported by strategic collaborations to enhance its product pipeline and market presence. Operating within the Healthcare sector, specifically the Drug Manufacturers - General industry, Amgen has demonstrated a strong track record of exceeding earnings expectations. In its most recent reported quarters, Amgen showed robust EPS performance, beating estimates in Q4 2024 ($5.31 actual vs $5.08 est), Q1 2025 ($4.90 vs $4.26), Q2 2025 ($6.02 vs $5.28), Q3 2025 ($5.64 vs $5.01), and Q4 2025 ($5.29 vs $4.83). Revenue also followed a generally upward trend, with actuals of $9.09B, $8.15B, $9.18B, $9.56B, and $9.87B for these respective quarters, indicating consistent top-line growth. The company has a notable beat/miss pattern, having exceeded analyst estimates for both EPS and revenue in the last several reported quarters, showcasing consistent operational strength. Historically, Amgen has maintained a strong YoY growth trajectory, consistently delivering positive earnings surprises, with an average surprise of nearly 12% over the past two quarters. Recent news indicates that investor focus is sharpening on Amgen's valuation, driven by the performance of Tepezza and upcoming trial results for MariTide, with Guggenheim raising its price target to $351 while maintaining a 'Neutral' rating. Despite a projected year-over-year EPS decline for the upcoming quarter, full-year revenue and EPS estimates indicate modest growth. Institutional investors have also been adjusting their positions. Key watch points for the next quarter will include the performance of key drugs like Tepezza, the impact of new product pipelines, and analyst reactions to upcoming trial results and financial guidance, particularly in the context of its competitive positioning in markets like obesity treatments.
